Blog
Announcing IPC’s New Leadership for 2025.
Welcome the newest leadership to the IPC Board of Directors! Meet incoming IPC President Bruce Strober, Vice…
Welcome the newest leadership to the IPC Board of Directors! Meet incoming IPC President Bruce Strober, Vice…
Read MoreINTERNATIONAL FEDERATION OF PSORIASIS ASSOCIATION CONFERENCE (IFPA) | STOCKHOLM, SWEDEN Friday, June 28 17:45 - 18:45…
Join Dr. Claudia de la Cruz, a dermatologist from Santiago, Chile, and Secretary of the International Psoriasis…
Read MoreIPC stands for accessible treatment and universal healthcare on World Psoriasis Day and beyond. Gain insights from…
Read MoreDiscover the latest updates on psoriasis from the World Congress of Dermatology (WCD) 2023, hosted in Singapore from…
Read MoreDiscover the latest updates on psoriasis from the World Congress of Dermatology (WCD) 2023, hosted in Singapore from…
View ReportDr. Claudia de la Cruz discusses the recent advances in the management of scalp psoriasis. La Dra. Claudia de la…
Watch VideoThe patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is…
Read MoreREUNIÓN ANUAL DE DERMATÓLOGOS LATINOAMERICANOS (RADLA) | CURITIBA, BRAZIL Friday, May 26 14:00 – 17:00 BRT 13:00…
El Dra. de la Cruz analiza por qué es importante que los médicos vean la psoriasis desde la perspectiva del paciente…
Watch VideoDr. de la Cruz discusses why it’s important for physicians to view psoriasis from the patient’s perspective and how…
Watch VideoWORLD CONGRESS OF DERMATOLOGY (WCD) | SINGAPORE Monday, July 3 14:30 - 17:30 SGT Program chairs: Claudia de la…
La XXXIX Reunión Anual de Dermatólogos Latinoamericanos (RADLA) se realizó de manera virtual del 2 al 5 de mayo,…
Read MoreThe 4th webinar in the series will center around the organization of psoriasis clinics now and in the future, including…
Watch VideoIPC's newly appointed appointed officers take their roles beginning January 1, 2022.
Read MoreBiologics and biosimilars have created many new options in psoriasis treatment for patients worldwide, but patients…
Read MoreView Report
The introduction of biological drugs for the treatment of patients with psoriasis has revolutionized treatment…
View ReportLatin American countries view biosimilar agents as an effective approach to curtail health-care expenditures while…
View Report| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.